Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate cancer: radical prostatectomy.

Joel B Nelson1, Herbert Lepor

  • 1Department of Urology, University of Pittsburgh School of Medicine, 5200 Centre Avenue, Suite 209, Pittsburgh, PA 15232, USA. nelsonjb@msx.upmc.edu

The Urologic Clinics of North America
|December 19, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Focal Cryo-Ablation for Treatment of Intermediate Favorable Risk (Grade Group 2) Prostate Cancer.

Urology·2026
Same author

Indigo Carmine Visualization Duration in Urine: A Randomized Kinetics Study.

Urogynecology (Philadelphia, Pa.)·2026
Same author

How urology can embrace the patient-centric precision focal therapy approach for localized prostate cancer.

Nature reviews. Urology·2026
Same author

Magnetic Resonance Imaging-Directed Stereotactic Body Radiation Therapy Microboost in Concert With Pelvic Nodal Irradiation for Prostate Cancer in the Higher-Risk Spectrum: Toxicity.

Advances in radiation oncology·2026
Same author

Evaluating indeterminate bone lesions and lymph nodes on PSMA-PET: a multidisciplinary consensus algorithm and 1-year implementation results.

European radiology·2026
Same author

MRI performance to identify clinically significant prostate cancer following focal cryo-ablation.

BJUI compass·2025
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Prostate cancer follow-up after surgery relies on pathology and prostate-specific antigen (PSA) levels. Early recurrence detection and treatment timing are key for managing prostate cancer survival.

Area of Science:

  • Oncology
  • Urology

Background:

  • Radical prostatectomy is a common treatment for prostate cancer.
  • Monitoring patients post-surgery is crucial for detecting recurrence.

Purpose of the Study:

  • To outline current best practices for prognosis and follow-up after radical prostatectomy.
  • To discuss the utility and limitations of various treatment modalities for recurrent prostate cancer.

Main Methods:

  • Review of prognostic factors including pathologic specimen analysis and prostate-specific antigen (PSA) kinetics.
  • Evaluation of the clinical utility of early recurrence imaging.
  • Analysis of adjuvant and salvage radiation therapy outcomes.
  • Discussion on the timing and efficacy of hormone therapy and chemotherapy.

Related Experiment Videos

Main Results:

  • Pathologic specimen analysis and PSA levels (time to detection, rate of rise) are vital for prognosis.
  • Early imaging for recurrence is often not clinically useful.
  • Adjuvant and salvage radiation offer benefits but no overall survival superiority.
  • Hormone therapy timing is empirical; chemotherapy shows limited current benefits.

Conclusions:

  • Prognosis and follow-up post-prostatectomy should integrate PSA kinetics and pathology.
  • Current treatment options for recurrence, including radiation and hormonal therapy, have limitations.
  • Future prostate cancer management will benefit from molecular risk stratification and response prediction.